HOME >> BIOLOGY >> NEWS
U-M scientists use 21st-century technology to probe secrets of M. tuberculosis

NEW ORLEANS University of Michigan microbiologists have created a virtual model of the human immune system that runs "in silico" to study what happens inside the lungs after people inhale Mycobacterium tuberculosis, the bacterium that causes TB.

The computer model is helping scientists learn more about this ancient pathogen, and why some people are able to fight off the infection, while others get sick. U-M scientists believe the answer could be hidden inside structures called granulomas, which immune cells build to surround and contain invading M. tuberculosis bacteria.

"Granulomas are the hallmark of tuberculosis," says Denise Kirschner Ph.D., an associate professor of microbiology and immunology in the U-M Medical School. "It's the immune system's fail-safe response to infection. If the immune system can't clear the pathogen, it gets out the masonry and walls it off."

Kirschner presented research results and an analysis of time-lapse computer animations showing granuloma formation at a May 26 seminar during the American Society for Microbiology's annual meeting held here this week.

"M. tuberculosis has been living with people for at least 4,000 years," says Kirschner. "Because the bug has had all those years to get to know us so well, it has evolved several effective ways to circumvent the immune system's ability to detect and kill invading pathogens. Scientific knowledge of how the immune system interacts with M. tuberculosis is slowly improving, but we are far from prevention or an effective vaccine. It's important to understand TB, because the disease is a serious and growing public health problem."

According to Kirschner, approximately 2 billion people worldwide are infected with M. tuberculosis, and the disease kills about 3 million people every year. In the early stages of infection, tuberculosis can be treated with powerful antibiotics, but there is no cure. And multi-drug-resistant strains, which are essentially
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
26-May-2004


Page: 1 2 3

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: scientists use century technology probe secrets tuberculosis

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: